A discharge petition for the Prescription Drug Fairness for Seniors Act has been issued by the Democratic members of the House of Representatives. The petition, which seeks to circumvent the committee system for the bill, had 144 signatures as of press time, short of the 218 votes needed to get the bill out of committee.
A discharge petition for the Prescription Drug Fairness for Seniors Act has been issued by the Democratic members of the House of Representatives. The petition, which seeks to circumvent the committee system for the bill, had 144 signatures as of press time, short of the 218 votes needed to get the bill out of committee.
The petition has come under fire from many House Democrats. "Discharging [the bill] to the floor would preclude consideration of a full range of solutions," read a "Dear Democratic Colleague" letter co written by Rush Holt (D-NJ) and Adam Smith (D-WA). "We expect it would only heighten the partisan debate on an issue too important to our seniors. We need action.... Signing a discharge petition could short-circuit the consideration of ideas on the very prescription drug benefit that each of us hopes to achieve this year."
If passed, the Prescription Drug Fairness for Seniors Act would require that retail pharmacies selling to senior citizens be given the same discount schedule, between 24 and 40%, that the U.S. government is given for their health agencies and clinics.
The bill itself has been criticized because it does not actually require the pharmacies it extends discounts to to pass those savings on to their customers. Said Reps. David Price (D-NC) and Calvin Dooly (D-CA) in their "Dear Democratic Colleague" letter, "Pharmacies could use the VA discount to subsidize the price of candy or toilet paper, or they could give lower prices to seniors. Nothing in the bill even requires the pharmacies to pass the savings along to anyone. The pharmacy could legally use the discount to improve profits." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.